{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-274950","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2026-06-18T11:12:58+00:00","discovered_at":"2026-06-18T11:15:01.307765+00:00","generated_at":"2026-06-18T11:15:12.687356+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enanta advances zelicapavir to registrational Phase 2b/3 trial in high-risk adults with RSV; pediatric Phase 2b planned","bullets":["Registrational Phase 2b/3 trial in high-risk adults (≥75 yrs, COPD, CHF) to start 4Q 2026; Phase 2b topline data expected 2027.","Phase 2b pediatric trial (28 days-36 months) to start 3Q 2026; topline data expected 2027; conducted with Penta Foundation and Chiang Mai University.","FDA End-of-Phase 2 meeting successful; trial design includes 800mg oral zelicapavir once daily for 7 days vs placebo.","Enanta estimates global market opportunity for oral RSV antiviral >$2B; US addressable population >3M patients.","No available treatment options for RSV; zelicapavir could be first antiviral therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-274950","json":"https://secwatch.observer/filing/0001193125-26-274950.json","markdown":"https://secwatch.observer/filing/0001193125-26-274950.md","text":"https://secwatch.observer/filing/0001193125-26-274950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000119312526274950/0001193125-26-274950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000119312526274950/d159604d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:15:12.687356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}